info@stemcellcure.in
Central Areolar Choroidal Dystrophy (CACD) is a rare inherited retinal disorder that gradually damages the macula, the central area of the retina responsible for detailed vision. The disease primarily affects the retinal pigment epithelium (RPE), photoreceptor cells, and the underlying choroid. As the condition progresses, it can lead to significant central vision loss while peripheral vision often remains relatively unaffected.
CACD usually develops during adulthood, with symptoms becoming noticeable between the ages of 30 and 60. Since the disease progresses slowly, early diagnosis and regular eye examinations play an important role in preserving vision and managing daily activities.
What is Central Areolar Choroidal Dystrophy?
Central Areolar Choroidal Dystrophy is an inherited macular disorder characterized by the gradual degeneration of the retinal pigment epithelium, photoreceptors, and choriocapillaris in the central retina. Over time, these changes create a well-defined area of retinal atrophy in the macula, resulting in reduced central vision.
The condition is most commonly associated with mutations in the PRPH2 (Peripherin-2) gene. It is typically inherited in an autosomal dominant pattern, meaning only one altered copy of the gene is needed for the disease to develop.
Causes of Central Areolar Choroidal Dystrophy
The primary cause of CACD is an inherited genetic mutation affecting proteins that maintain the health and stability of retinal cells.
Common causes and risk factors include:
• Mutation in the PRPH2 (Peripherin-2) gene
• Family history of inherited retinal disorders
• Progressive degeneration of the retinal pigment epithelium
• Loss of photoreceptor cells
• Atrophy of the underlying choroid
Because CACD is a genetic disorder, it is not caused by poor nutrition, excessive screen use, or aging alone.
Symptoms of Central Areolar Choroidal Dystrophy
Symptoms generally appear gradually and become more noticeable as the disease advances.
Common symptoms include:
• Blurred central vision
• Difficulty reading small print
• Trouble recognizing faces
• Distorted central vision
• Reduced visual clarity
• Difficulty performing detailed tasks
• Decreased color perception
• Central blind spots in advanced stages
Peripheral vision usually remains preserved, allowing patients to maintain mobility despite central vision loss.
Diagnosis of Central Areolar Choroidal Dystrophy
An ophthalmologist can diagnose CACD using a combination of clinical examination and advanced retinal imaging techniques.
Diagnostic tests may include:
• Comprehensive eye examination
• Dilated retinal evaluation
• Optical Coherence Tomography (OCT)
• Fundus photography
• Fundus Autofluorescence (FAF)
• Fluorescein angiography
• Optical Coherence Tomography Angiography (OCTA)
• Visual field testing
• Electroretinography (ERG) in selected cases
• Genetic testing to confirm PRPH2 mutations
These tests help differentiate CACD from age-related macular degeneration and other inherited retinal disorders.
Treatment Options for Central Areolar Choroidal Dystrophy
At present, there is no permanent cure for Central Areolar Choroidal Dystrophy. Treatment is focused on preserving remaining vision, monitoring disease progression, and improving quality of life.
Low Vision Rehabilitation
Patients may benefit from magnifying devices, electronic reading systems, large-print materials, and digital accessibility tools that improve daily functioning.
Regular Eye Examinations
Routine retinal evaluations allow eye specialists to monitor disease progression and identify any associated complications early.
Healthy Eye Care
Maintaining a balanced diet rich in antioxidants, protecting the eyes from excessive ultraviolet (UV) exposure, avoiding smoking, and managing overall health may help support retinal function.
Emerging Therapies
Researchers continue to investigate gene therapy, stem cell therapy, retinal cell transplantation, and other regenerative treatments for inherited retinal diseases. Although these approaches remain under clinical investigation, they offer hope for slowing disease progression and restoring retinal function in the future.
Living with Central Areolar Choroidal Dystrophy
Living with CACD often requires adapting to gradual vision changes. Low vision rehabilitation, assistive technologies, proper lighting, and regular follow-up appointments can help patients maintain independence. Individuals with a family history of inherited retinal diseases may also benefit from genetic counseling and family screening.
Conclusion
Central Areolar Choroidal Dystrophy (CACD) is a rare inherited retinal disorder that causes progressive degeneration of the macula and central vision. Although there is currently no definitive cure, early diagnosis, regular monitoring, supportive vision care, and ongoing advances in gene and stem cell research provide hope for improved treatment options. With comprehensive eye care and rehabilitation, many individuals can continue to live active and productive lives.
Frequently Asked Questions (FAQs)
1. What is Central Areolar Choroidal Dystrophy (CACD)?
CACD is a rare inherited retinal disorder that gradually damages the macula, leading to progressive central vision loss.
2. What causes Central Areolar Choroidal Dystrophy?
The condition is most commonly caused by mutations in the PRPH2 (Peripherin-2) gene, which affect the normal structure and function of retinal cells.
3. Is CACD hereditary?
Yes. CACD is usually inherited in an autosomal dominant pattern and may run in families.
4. How is Central Areolar Choroidal Dystrophy diagnosed?
Diagnosis includes a comprehensive eye examination, OCT, fundus imaging, fluorescein angiography, OCTA, and genetic testing.
5. Is there a cure for Central Areolar Choroidal Dystrophy?
Currently, there is no permanent cure. Treatment focuses on monitoring the disease, preserving vision, and improving quality of life through supportive care.
6. Can stem cell therapy help treat CACD?
Stem cell therapy is being investigated as a potential treatment for inherited retinal diseases. While research is encouraging, it is still undergoing clinical evaluation and is not yet considered a standard treatment.